K2 Therapeutics
Singapore’s biotechnology firm K2 Therapeutics raises $50M in seed financing from MPM BioImpact
K2 Therapeutics, a Singapore-based biotechnology company, has raised $50 million in seed financing from MPM BioImpact, the U.S. investment firm that founded the company in 2024.
August 12, 2026
Fujitsu and Paradigm test AI screening for Japan trials
November 20, 2026
MetaComp adds about $10M from Tether and Further
November 20, 2026
Fujitsu and Paradigm test AI screening for Japan trials
November 20, 2026
MetaComp adds about $10M from Tether and Further
November 20, 2026




